The German biotech company, CureVac has launched the final stages of the vaccine against COVID-19. The large-scale trial is expected to involve 35,000 volunteer participants, ranging from Europe to Latin America. The participants are 18 years of age or above.
This vaccine is supposed to be similar in mRNA platform, to the vaccines developed by companies such as BioNTech/Pfizer and Moderna. However, unlike those vaccines, which need to be kept at minus 70 degrees Celsius, particularly during transportation, the Garman developed CureVac vaccine can remain stable at standard fridge temperature for nearly three months.
This is good news for many countries which don’t possess enough cold storage facilities to either transport or store the BioNTech/Pfizer and Moderna vaccines.